MX2020007270A - Formulacion parenteral que comprende siponimod. - Google Patents

Formulacion parenteral que comprende siponimod.

Info

Publication number
MX2020007270A
MX2020007270A MX2020007270A MX2020007270A MX2020007270A MX 2020007270 A MX2020007270 A MX 2020007270A MX 2020007270 A MX2020007270 A MX 2020007270A MX 2020007270 A MX2020007270 A MX 2020007270A MX 2020007270 A MX2020007270 A MX 2020007270A
Authority
MX
Mexico
Prior art keywords
siponimod
parenteral formulation
relates
present
solution
Prior art date
Application number
MX2020007270A
Other languages
English (en)
Inventor
Rajesh Kumar
Mandala Rayabandla Sunil Kumar
Henricus Lambertus Gerardus Maria Tiemessen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020007270A publication Critical patent/MX2020007270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica de siponimod que puede administrarse por vía parenteral. En particular, la presente invención se refiere a una solución parenteral que comprende siponimod y a un método de preparación de dicha solución.
MX2020007270A 2017-09-27 2018-09-26 Formulacion parenteral que comprende siponimod. MX2020007270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711034371 2017-09-27
PCT/IB2018/057425 WO2019064185A1 (en) 2017-09-27 2018-09-26 PARENTERAL FORMULATION COMPRISING SITOMOD

Publications (1)

Publication Number Publication Date
MX2020007270A true MX2020007270A (es) 2020-08-17

Family

ID=63857992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007270A MX2020007270A (es) 2017-09-27 2018-09-26 Formulacion parenteral que comprende siponimod.

Country Status (11)

Country Link
US (1) US11628137B2 (es)
EP (1) EP3687498A1 (es)
JP (1) JP7271517B2 (es)
KR (1) KR20200059221A (es)
CN (1) CN111107837A (es)
AU (2) AU2018341136A1 (es)
BR (1) BR112020005703A2 (es)
CA (1) CA3074043A1 (es)
IL (1) IL273469A (es)
MX (1) MX2020007270A (es)
WO (1) WO2019064185A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220409544A1 (en) * 2019-11-22 2022-12-29 Leiutis Pharmaceuticals Llp Stable parenteral formulations of duloxetine
BR112023024578A2 (pt) * 2021-05-26 2024-02-06 Daewoong Pharmaceutical Co Ltd “formulação para injeção compreendendo o composto 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina ou um sal farmaceuticamente aceitável do mesmo, uma ciclodextrina e um agente isotonizante, bem como uso terapêutico do referido composto

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4644364B2 (ja) * 1998-02-05 2011-03-02 ノバルティス アーゲー エポシロン組成物
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
ATE526032T1 (de) 2003-12-11 2011-10-15 Ares Trading Sa Stabilisierte flüssige interferon-formulierungen
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
EP1965807A4 (en) 2005-11-23 2010-10-27 Epix Delaware Inc S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE
KR20170062554A (ko) * 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
CN102342931B (zh) * 2010-07-29 2014-04-23 江苏恒瑞医药股份有限公司 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法
EP3590507A1 (en) 2011-01-07 2020-01-08 Novartis AG Immunosuppressant formulations
CN106163502B (zh) * 2014-04-10 2020-12-01 诺华股份有限公司 免疫抑制剂配方
EP3364947B1 (en) 2015-10-20 2021-09-15 B. Braun Melsungen AG Aqueous composition comprising dantrolene
WO2017085696A1 (en) * 2015-11-20 2017-05-26 Leiutis Pharmaceuticals Pvt Ltd Parenteral formulations of melphalan

Also Published As

Publication number Publication date
JP2020535143A (ja) 2020-12-03
US11628137B2 (en) 2023-04-18
WO2019064185A1 (en) 2019-04-04
IL273469A (en) 2020-05-31
US20200230049A1 (en) 2020-07-23
AU2021269450A1 (en) 2021-12-16
KR20200059221A (ko) 2020-05-28
AU2018341136A1 (en) 2020-03-12
RU2020114619A (ru) 2021-10-27
AU2021269450B2 (en) 2023-07-27
CA3074043A1 (en) 2019-04-04
BR112020005703A2 (pt) 2020-10-20
CN111107837A (zh) 2020-05-05
JP7271517B2 (ja) 2023-05-11
EP3687498A1 (en) 2020-08-05
RU2020114619A3 (es) 2021-12-24

Similar Documents

Publication Publication Date Title
PH12018500947A1 (en) Crystal form, preparation method and intermediate of dihydropyrido ring compound
MX2023001189A (es) Produccion de acido ribonucleico libre de celulas.
GEP20207075B (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2016009332A (es) Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
MX370628B (es) Composiciones y metodos para tratar las espinillas.
MY193444A (en) Cell-free production of ribonucleic acid
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
PH12016501841A1 (en) Immunosuppressant formulation
SA517390475B1 (ar) نظام أكياس متعددة وطريقة لتحضير مكونات الدم
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MA40313A (fr) Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
IN2014CH00840A (es)
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
IN2013MU01985A (es)
IN2014MU00916A (es)
IN2014CH00151A (es)
MX2020007270A (es) Formulacion parenteral que comprende siponimod.
PH12016500847A1 (en) Multi-particulate drug delivery system
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
MX2015016603A (es) Composiciones de corticosteroides.
MA40447A (fr) Composition pharmaceutique orale d'isotrétinoïne
PH12017501979A1 (en) Pharmaceutical compound